Mersana Therapeutics, Inc.
MRSNDelisted Jan 6, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001442836
Mersana Therapeutics, Inc. was delisted on Jan 6, 2026; its insiders filed their last Form 4 on Jan 6, 2026; 51 institutions reported holding it in 13F filings for Q4 2025, worth $64.8M in total; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 51
- Q4 2025, +2 vs. previous quarter
- 13F value
- $64.8M
- Reported value at the end of Q4 2025
- Superinvestors holding
- 0
- At the end of Q4 2025
Superinvestors holding MRSN, Q4 2025
No superinvestor reported holding MRSN at the end of Q4 2025.
Latest insider trades
Open-market purchases and sales by Mersana Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 28, 2025 (view filing) | Oct 27 | 1 day | Bala MohanSVP, Chief Development Officer | SSale | −77 | $9.90 | −$762.3 | −2.6%2.92K after | 10b5-1 |
| Sep 15, 2025 (view filing) | Sep 12 | 3 days | Huber Martin H. Jr.President, CEO | SSale | −2.01K | $7.31 | −$14.7K | −17.4%9.57K after | 10b5-1 |
| Jan 17, 2025 (view filing) | Jan 16 | 1 day | Mandelia AshishVP, Chief Accounting Officer | SSale | −3.55K | $0.58 | −$2.06K | −5.8%57.5K after | 10b5-1 |
| Jan 17, 2025 (view filing) | Jan 16 | 1 day | Protopapas AnnaDirector | SSale | −8.64K | $0.58 | −$5.01K | −4.9%168.0K after | 10b5-1 |
| Jan 17, 2025 (view filing) | Jan 16 | 1 day | Lowinger Timothy BSVP, Chief Sci.&Tech. Officer | SSale | −8.05K | $0.58 | −$4.67K | −3.0%257.7K after | 10b5-1 |
| Jan 17, 2025 (view filing) | Jan 16 | 1 day | Huber Martin H. Jr.President, CEO | SSale | −4.51K | $0.58 | −$2.62K | −3.5%122.9K after | 10b5-1 |
| Jan 17, 2025 (view filing) | Jan 16 | 1 day | DeSchuytner BrianSVP, COO & CFO | SSale | −8.47K | $0.58 | −$4.91K | −6.5%121.4K after | 10b5-1 |
| Jan 17, 2025 (view filing) | Jan 16 | 1 day | Carvajal AlejandraSVP, Chief Legal Officer | SSale | −5.10K | $0.58 | −$2.96K | −6.1%78.3K after | 10b5-1 |
| Jan 17, 2025 (view filing) | Jan 16 | 1 day | Bala MohanSVP, Chief Development Officer | SSale | −5.94K | $0.58 | −$3.44K | −7.9%68.9K after | 10b5-1 |
| Jan 16, 2025 (view filing) | Jan 15 | 1 day | Protopapas AnnaDirector | SSale | −6.19K | $0.63 | −$3.90K | −3.8%155.4K after | 10b5-1 |
Top 10 13F holders, Q4 2025
The largest institutional positions in Mersana Therapeutics, Inc. at the end of Q4 2025; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nextech Invest, Ltd. | 482,689 | $14.0M | 1.35% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 346,545 | $10.0M | 0.77% | 00.0% | Unchanged |
| Vanguard Group Inc | 210,301 | $6.08M | 0.00% | −92,252−30.5% | Reduced |
| Rock Springs Capital Management LP | 152,586 | $4.41M | 0.23% | 00.0% | Unchanged |
| Alamea Verwaltungs GmbH | 24,165 | $3.34M | 2.25% | −405,860−94.4% | Reduced |
| Acadian Asset Management LLC | 110,882 | $3.21M | 0.01% | −31,478−22.1% | Reduced |
| Affinity Asset Advisors, LLC | 100,000 | $2.89M | 0.21% | +100,000 | New |
| BlackRock, Inc. | 69,210 | $2.00M | 0.00% | −26,983−28.1% | Reduced |
| Bank of America Corp | 65,749 | $1.90M | 0.00% | −648−1.0% | Reduced |
| Millennium Management LLC | 63,305 | $1.83M | 0.00% | −14,684−18.8% | Reduced |